Propanc Health Group Corp. (OTCQB: PPCH) is an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients suffering from solid tumors, such as those resulting from pancreatic, ovarian, and colorectal cancers. The company recently announced results from studies for its lead product, PRP, confirming a synergistic response to a broad range of cancer indications, including kidney, melanoma, brain, prostate, liver, uterine and lung cancers. The data provides compelling evidence that PRP has the potential to fight a broad range of cancer types, some with significant unmet medical needs. The company will continue to investigate PRP’s efficacy in these indications through clinical trials.
Moreover, data from the recent cell line studies tested at the R&D facility of Propanc’s contract research partner, vivoPharm LLC, which is headquartered in Hershey, Pennsylvania, showed a synergistic response between the two active components, trypsinogen and chymotrypsinogen, further strengthening its lead patent claims in key jurisdictions throughout North America and Europe.
The company has also confirmed a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, currently scheduled for the end of April. The purpose of the meeting is to discuss Propanc’s ongoing development activities for PRP, including preparation and structure of animal safety/toxicology studies and its proposed early stage patient trials, together with supporting activities.
Propanc has developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Its products involve or employ proenzymes, which are inactive precursors of enzymes.
Learn more by visiting www.propanc.com
